Long-Term Dupilumab Benefits Adolescents with Eczema

Release Date:
Wednesday, October 9, 2019 12:01 am EDT

Terms:
British Journal of Dermatology  Wiley Research Headlines  All Journals and Research  Dermatology  Health Sciences

Dateline City:
Hoboken, NJ

Contacts:
Penny Smith +44 (0) 1243 770448 (UK) newsroom@wiley.com

Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab. The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.

Results from a phase IIa open-label trial and a subsequent phase III open-label extension trial reinforce findings from an earlier short-term trial that adolescents with moderate-to-severe atopic dermatitis, or eczema, can experience significant improvements with dupilumab. The results from these latest studies, which are reported in the British Journal of Dermatology, demonstrate the long-term safety and efficacy of the medication for up to 52 weeks of treatment.

Dupilumab works by stopping the action of certain substances in the body that cause the symptoms of eczema. Specifically, it is a monoclonal antibody against interleukin-4 receptor alpha.

“Adolescents with moderate-to-severe atopic dermatitis have a high disease burden that negatively affects quality of life, and patients are in need of therapies that can be used long-term,” said senior author Ashish Bansal, MD, of Regeneron Pharmaceuticals, Inc., in Tarrytown, New York. “Results from these trials show that dupilumab provides substantial and sustained clinical benefit to these patients with an acceptable safety profile.”

Additional Information


About Journal

he BJD strives to publish the highest-quality dermatological research. In so doing, the Journal aims to advance the understanding, management and treatment of skin disease in order to improve the outcomes of patient care. The main focus of the BJD (described in a position statement published in the June 2015 issue) is to publish the highest-quality research encompassing the following:

- Clinical trials that are registered before recruitment starts and report fully according to the CONSORT guidelines.
- Clinical studies that include epidemiology, qualitative research and mixed methods that conform to the STROBE and SRQR reporting guidelines.
- Translational research that describes basic and applied science of potential clinical relevance.
- Systematic reviews following the PRISMA statement (http://www.prisma-statement.org/), MOOSE guidelines or the ENTREQ statement.

About Wiley

Wiley drives the world forward with research and education. Through publishing, platforms and services, we help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company’s website can be accessed at www.wiley.com.

Language:
English
